Next Article in Journal
Therapeutic Potential of Differentiated Mesenchymal Stem Cells for Treatment of Osteoarthritis
Next Article in Special Issue
Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis?
Previous Article in Journal
Terminal Mannose Residues in Seminal Plasma Glycoproteins of Infertile Men Compared to Fertile Donors
Previous Article in Special Issue
Mental Health in Multiple Sclerosis Patients without Limitation of Physical Function: The Role of Physical Activity
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2015, 16(7), 14951-14960;

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
Klinik für Neurologie, Caritas Krankenhaus Bad Mergentheim gGmbH, Uhlandstr. 7, 97980 Bad Mergentheim, Germany
Author to whom correspondence should be addressed.
Academic Editor: Christoph Kleinschnitz
Received: 19 May 2015 / Revised: 23 June 2015 / Accepted: 26 June 2015 / Published: 2 July 2015
(This article belongs to the Special Issue Advances in Multiple Sclerosis)
Full-Text   |   PDF [1872 KB, uploaded 2 July 2015]   |  


Interferons are widely used platform therapies as disease-modifying treatment of patients with multiple sclerosis. Although interferons are usually safe and well tolerated, they frequently cause dermatological side effects. Here, we present a multiple sclerosis (MS) patient treated with interferon-β who developed new-onset psoriasis. Both her MS as well as her psoriasis finally responded to treatment with fumarates. This case illustrates that interferons not only cause local but also systemic adverse events of the skin. These systemic side effects might indicate that the Th17/IL-17 axis plays a prominent role in the immunopathogenesis of this individual case and that the autoimmune process might be deteriorated by further administration of interferons. In conclusion, we think that neurologists should be aware of systemic cutaneous side effects and have a closer look on interferon-associated skin lesions. Detection of psoriasiform lesions might indicate that interferons are probably not beneficial in the individual situation. We suggest that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs. View Full-Text
Keywords: multiple sclerosis; interferon-β; therapy; cutaneous adverse events; psoriasis multiple sclerosis; interferon-β; therapy; cutaneous adverse events; psoriasis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kolb-Mäurer, A.; Goebeler, M.; Mäurer, M. Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis. Int. J. Mol. Sci. 2015, 16, 14951-14960.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top